PMID: 6109855Jan 24, 1981Paper

Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis

Lancet

Abstract

Five 6-month antituberculosis regimens, allocated at random to patients with acid-fast bacilli in their sputum on microscopy, were studied. Four, given three times a week from the start, contained isoniazid and rifampicin together with (1) streptomycin, pyrazinamide, and ethambutol, (2) streptomycin and pyrazinamide, (3) streptomycin and ethambutol, or (4) pyrazinamide and ethambutol. The fifth was daily isoniazid, rifampicin, pyrazinamide, and ethambutol. All 833 patients with drug-sensitive strains of bacilli before treatment had a favourable bacteriological response during chemotherapy, and the bacteriological relapse rates during 12 months after stopping chemotherapy were 2% or less for all regimens except thrice-weekly isoniazid, rifampicin, streptomycin, and ethambutol (the only regimen without pyrazinamide), which had a relapse rate of 8%. The results were equally good for the 138 patients with bacilli resistant to isoniazid, streptomycin, or both drugs initially. The incidence of potentially serious toxicity was low. The daily regimen is relevant to programmes in which patients self-administer their drugs, and the 3 pyrazinamide-containing intermittent regimens are relevant to fully supervised outpatient programmes.

Citations

Jul 31, 2013·Indian Journal of Pediatrics·Pushpa PanigattiT A Shepur
Dec 19, 2009·Indian Pediatrics·C K IndumathiS Lewin
Jul 1, 1984·European Journal of Obstetrics, Gynecology, and Reproductive Biology·L C TangV C Wong Taam
May 6, 1995·Lancet·F DurandJ Bernuau
Jan 1, 1997·Pharmacology & Therapeutics·A D Harries
Jan 25, 2002·Annals of the New York Academy of Sciences·P Ormerod
May 5, 2010·Antimicrobial Agents and Chemotherapy·Jotam G Pasipanodya, Tawanda Gumbo
Aug 16, 2006·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
Nov 7, 2006·American Journal of Respiratory and Critical Care Medicine·Cesare Saltini
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
May 10, 2003·American Journal of Respiratory and Critical Care Medicine·William J Burman
Jul 8, 2008·Nutrition & Metabolism·Sude EminzadeFikret V Izzettin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.